BioVie, Inc.
(NASDAQ : BIVI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -1.14%570.082.7%$666.95m
ILMNIllumina, Inc. -0.30%319.473.5%$656.48m
AMGNAmgen, Inc. -0.93%228.961.3%$593.66m
ARRYArray BioPharma Inc. 6.08%40.8414.2%$532.69m
GILDGilead Sciences, Inc. -0.36%60.331.0%$505.17m
MRNAModerna, Inc. -1.67%70.120.0%$495.28m
VRTXVertex Pharmaceuticals, Inc. -0.66%213.131.9%$476.49m
IMMUImmunomedics, Inc. 0.09%87.8011.0%$388.12m
NVAXNovavax, Inc. -4.92%93.5396.5%$310.04m
ALXNAlexion Pharmaceuticals, Inc. -3.00%120.282.0%$288.79m
BIIBBiogen, Inc. -0.13%266.771.6%$257.27m
EXASEXACT Sciences Corp. -2.11%100.8520.7%$224.50m
BNTXBioNTech SE -6.72%88.010.0%$210.30m
SRNESorrento Therapeutics, Inc. -3.04%7.971.4%$186.73m
SGENSeagen Inc. 1.23%200.466.0%$172.18m

Company Profile

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.